January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Diagnosis & Disease Information
Vonoprazan Looks Promising for Nonerosive Gastroesophageal Reflux Disease
The randomized, double-blind, multicenter PHALCON-NERD-301 study included 776 adults with symptomatic NERD.
FDA’s Decision on Vonoprazan Delayed Due to Nitrosamine Impurity
The FDA has established an acceptable daily intake limit for NVP of 96ng/day.
Eradicating H. pylori Cuts Aspirin-Related Peptic Ulcer Bleeding in the Short Term
Protection against aspirin-associated peptic ulcer bleeding in older adults lost after the first 2.5 years
Konvomep Approved for Active Benign Gastric Ulcer, Upper GI Bleed Risk Reduction
Konvomep contains 2mg of omeprazole, a proton pump inhibitor, and 84mg of sodium bicarbonate per mL after reconstitution.
Glycopyrrolate Injection 0.6mg/3mL Now Available in Ready-to-Administer Prefilled Syringe
The Simplist ready-to-administer prefilled syringes minimize preparation steps for clinicians.
Antacid, Constipation Products Recalled Due to Microbial Contamination
The recalled lots were distributed to Major Pharmaceuticals Distribution Center between July 1, 2020 and October 31, 2021.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
FDA Approves OTC Omeprazole in Mini Capsule Form
Perrigo received final approval to manufacture Omeprazole Magnesium Delayed-Release Mini Capsules, 20mg.
FDA to Review Vonoprazan for Erosive Esophagitis
Vonoprazan is an oral small molecule potassium-competitive acid blocker.
